Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $311.25 million. The enterprise value is $313.98 million.

Market Cap	311.25M
Enterprise Value	313.98M

Important Dates

The next estimated earnings date is Monday, August 11, 2025, after market close.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Citius Oncology has 71.55 million shares outstanding. The number of shares has increased by 3.82% in one year.

Current Share Class	71.55M
Shares Outstanding	71.55M
Shares Change (YoY)	+3.82%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.17%
Float	5.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	9.03
P/TBV Ratio	8.70
P/FCF Ratio	n/a
P/OCF Ratio	2,454.87
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.36, with a Debt / Equity ratio of 0.11.

Current Ratio	0.36
Quick Ratio	n/a
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -93.64% and return on invested capital (ROIC) is -53.05%.

Return on Equity (ROE)	-93.64%
Return on Assets (ROA)	-22.41%
Return on Invested Capital (ROIC)	-53.05%
Return on Capital Employed (ROCE)	-60.35%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Citius Oncology has paid $816,480 in taxes.

Income Tax	816,480
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -61.71% in the last 52 weeks. The beta is -0.06, so Citius Oncology's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	-61.71%
50-Day Moving Average	1.28
200-Day Moving Average	1.15
Relative Strength Index (RSI)	89.89
Average Volume (20 Days)	3,125,232

Short Selling Information

The latest short interest is 113,580, so 0.16% of the outstanding shares have been sold short.

Short Interest	113,580
Short Previous Month	25,500
Short % of Shares Out	0.16%
Short % of Float	2.06%
Short Ratio (days to cover)	0.52

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-25.16M
Pretax Income	n/a
Net Income	-25.98M
EBITDA	n/a
EBIT	-25.16M
Earnings Per Share (EPS)	-$0.37

Full Income Statement

Balance Sheet

The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.

Cash & Cash Equivalents	112
Total Debt	3.80M
Net Cash	-3.80M
Net Cash Per Share	-$0.05
Equity (Book Value)	35.64M
Book Value Per Share	0.50
Working Capital	-31.70M

Full Balance Sheet

Cash Flow

Operating Cash Flow	126,353
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.82%
Shareholder Yield	-3.82%
Earnings Yield	-8.38%
FCF Yield	n/a

Analyst Forecast

The average price target for Citius Oncology is $6.00, which is 37.93% higher than the current price. The consensus rating is "Buy".

Price Target	$6.00
Price Target Difference	37.93%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3